As intravenous use of albumin has been shown not to decrease mortality in the critically ill [32], further studies are needed to determine if there are any other therapeutic options that would specifically target the worse prognosis associated with hypoalbuminemia in cardiogenic shock. This evidence concerns the gene ALB and Hypoalbuminemia.